BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 624904)

  • 1. Modulation of the formation of the amplification convertase of complement, C3b, Bb, by native and commercial heparin.
    Weiler JM; Yurt RW; Fearon DT; Austen KF
    J Exp Med; 1978 Feb; 147(2):409-21. PubMed ID: 624904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
    Waldo FB; Forristal J; Beischel L; West CD
    J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane.
    Fearon DT
    Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5867-71. PubMed ID: 293688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heparin prevents formation of the human C3 amplification convertase by inhibiting the binding site for B on C3b.
    Maillet F; Kazatchkine MD; Glotz D; Fischer E; Rowe M
    Mol Immunol; 1983 Dec; 20(12):1401-4. PubMed ID: 6558419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of the formation of the human amplification C3 convertase of complement by polycations.
    Maillet F; Kazatchkine MD
    Immunology; 1983 Sep; 50(1):27-33. PubMed ID: 6554235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of the function of activated properdin by squid chondroitin sulfate E glycosaminoglycan and murine bone marrow-derived mast cell chondroitin sulfate E proteoglycan.
    Wilson JG; Fearon DT; Stevens RL; Seno N; Austen KF
    J Immunol; 1984 Jun; 132(6):3058-63. PubMed ID: 6427331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
    Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
    Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of the formation of the human C-3 amplification convertase of complement by polyelectrolytes.
    Kazatchkine MD; Maillet F; Fischer E; Glotz D
    Agents Actions; 1981 Dec; 11(6-7):645-6. PubMed ID: 6918183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of the C3 nephritic factor stabilized C3/C5 convertase of complement by purified human erythrocyte C3b receptor.
    Daha MR; Kok DJ; Van Es LA
    Clin Exp Immunol; 1982 Oct; 50(1):209-14. PubMed ID: 6216999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eosinophil granule major basic protein regulates generation of classical and alternative-amplification pathway C3 convertases in vitro.
    Weiler JM; Gleich GJ
    J Immunol; 1988 Mar; 140(5):1605-10. PubMed ID: 3346544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.
    Fearon DT
    Proc Natl Acad Sci U S A; 1978 Apr; 75(4):1971-5. PubMed ID: 273923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes.
    Medof ME; Kinoshita T; Nussenzweig V
    J Exp Med; 1984 Nov; 160(5):1558-78. PubMed ID: 6238120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact.
    Pryzdial EL; Isenman DE
    J Biol Chem; 1987 Feb; 262(4):1519-25. PubMed ID: 3643213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium.
    Fishelson Z; Müller-Eberhard HJ
    J Immunol; 1982 Dec; 129(6):2603-7. PubMed ID: 6923908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
    Pangburn MK; Müller-Eberhard HJ
    Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
    Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
    Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control of the amplification convertase of complement by the plasma protein beta1H.
    Weiler JM; Daha MR; Austen KF; Fearon DT
    Proc Natl Acad Sci U S A; 1976 Sep; 73(9):3268-72. PubMed ID: 1067618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
    Fearon DT; Austen KF
    J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase.
    Pangburn MK; Müller-Eberhard HJ
    Biochem J; 1986 May; 235(3):723-30. PubMed ID: 3638964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The inhibitory effect of factor J on the alternative complement pathway.
    González-Rubio C; Jiménez-Clavero MA; Fontán G; López-Trascasa M
    J Biol Chem; 1994 Oct; 269(42):26017-24. PubMed ID: 7929312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.